Navigation Links
Report says new evidence could tip the balance in aspirin cancer prevention care
Date:4/9/2012

ATLANTAApril 10, 2012A new report by American Cancer Society scientists says new data showing aspirin's potential role in reducing the risk of cancer death bring us considerably closer to the time when cancer prevention can be included in clinical guidelines for the use of aspirin in preventative care. The report, published early online in Nature Reviews Clinical Oncology, says even a 10% reduction in overall cancer incidence beginning during the first 10 years of treatment could tip the balance of benefits and risks favorably in average-risk populations.

Current guidelines for the use of aspirin in disease prevention consider only its cardiovascular benefits, weighed against the potential harm from aspirin-induced bleeding. While daily aspirin use has also been convincingly shown to reduce the risk of colorectal cancer and recurrence of adenomatous polyps, these benefits alone do not outweigh harms from aspirin-induced bleeding in average-risk populations. But recently published secondary analyses of cardiovascular trials have provided the first randomized evidence that daily aspirin use may also reduce the incidence of all cancers combined, even at low doses (75-100 mg daily).

The current review, led by Michael J. Thun, M.D., vice president emeritus of epidemiology and surveillance research for the American Cancer Society was not designed as a comprehensive review of the literature, but instead is a focused discussion of the key outstanding issues in using aspirin as a cancer prevention tool.

The report says recently published meta-analyses of results from randomized trials of daily aspirin treatment to prevent vascular events have provided provocative evidence that daily aspirin at doses of 75 mg and above might lower both overall cancer incidence and overall cancer mortality.

In six primary prevention trials of daily low-dose aspirin, randomization to aspirin treatment was associated with an approximately 20% reduction in overall cancer incidence between 3 and 5 years after initiation of the intervention (metaodds ratio [OR] = 0.81; 95% CI 0.67-0.98) and a 30% reduction during follow up more than 5 years after randomization (meta-OR = 0.70; 95% CI 0.56-0.88). Cancer mortality was also reduced during study follow up that happened more than 5 years after the start of aspirin use (meta-OR = 0.63; 95% CI 0.49-0.82) in analyses that included 34 trials of daily aspirin at various doses. Surprisingly, the size of the observed benefit did not increase with daily doses of aspirin above 75-100 mg. Notably, these meta-analyses excluded results from the Women's Health Study (WHS), a large 10-year-long trial of 100 mg of aspirin taken every other day, which reported no reduction in cancer incidence or mortality.

"The accumulating data from randomized clinical trials provide an exciting opportunity to reconsider the potential role of aspirin in cancer prevention," write the authors. They say several important questions remain unanswered, such as the exact magnitude of the overall cancer benefit and which individual cancer sites contribute to this benefit. "However, these new data bring us considerably closer to the time when cancer prevention can be integrated into the clinical guidelines for prophylactic treatment following regulatory review by the FDA and the European Medicines Agency."


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
2. Preteens More Likely to Report HPV Vaccine Side Effects
3. Young girls more likely to report side effects after HPV vaccine
4. Fewer U.S. Med Students Choose Psychiatry: Report
5. IOM report identifies public health actions for improving the lives of those with epilepsy
6. U.S. Autism Rate Rises to 1 in 88 Children, CDC Reports
7. Rare medical phenomenon of systemic tumor disappearance following local radiation treatment reported in a patient with metastatic melanoma
8. Report suggests ways to improve health-care provider report cards
9. Urban Forests Disappearing: Report
10. Efforts to Improve Research on Kids Drugs Paying Off: Report
11. Report examines what US can learn from EU chemicals law
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... ... Carnival Vista – the line’s largest cruise ship ever. To help guests ... an infographic spotlighting the Carnival Vista ’s most exciting features and ...
(Date:5/2/2016)... ... ... It has just been announced Jack Uldrich, renowned futurist and ... of May. , Uldrich is the author of 11 books and a regular guest ... the Science Channel’s FutureScape and Discovery Channel’s Inside Out. , Known the world over ...
(Date:5/2/2016)... Dallas, Texas (PRWEB) , ... May 02, 2016 ... ... Volume 3, Issue 1 of Patient Experience Journal (PXJ), an international, open ... patient experience. With almost half the issue representing international (non-US) based authors, the ...
(Date:5/2/2016)... ... 02, 2016 , ... Beanfields, PBC, makers of Beanfields Bean ... students at University of Colorado in Boulder to create new advertising campaigns. , ... the School of Journalism, who selected Beanfields as the brand on which to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life Insurance ... understand life insurance throughout various life stages. , The site launched on April ... calculator and content specific to the times when life insurance matters most. , ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... Jersey , April 29, 2016 ... Suite for Life Sciences, Product Development Capabilities in ... Life Science Customer Base . ... provider, today announced the acquisition of Skura Corporation,s ... global leader in adaptive sales enablement technology for ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
Breaking Medicine Technology: